Cytokine-induced Killer Study for Patients With Stage II Melanoma
Status:
Not yet recruiting
Trial end date:
2040-08-01
Target enrollment:
Participant gender:
Summary
For investigators' current experimental clinical trial, patients are given 4 injections of
ipilimumab, given 3 weeks apart x 4 injections with or without cytokine-induced killer
therapy. Investigators propose to test this dual therapy in patients with melanoma who have
known stage I, metastatic melanoma. Investigators hypothesize that this form of combinatorial
immunotherapy will result in tumor stabilization or shrinkage, significant prolongation of
progression-free, disease-free or overall survival compared to the use of ipilimumab alone